iRadimed (NASDAQ:IRMD) CFO Sells $1,459,350.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CFO John Glenn sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the transaction, the chief financial officer owned 7,362 shares of the company’s stock, valued at $716,248.98. This trade represents a 67.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

iRadimed Trading Down 1.2%

IRMD stock traded down $1.15 during trading on Friday, hitting $96.23. The company had a trading volume of 64,845 shares, compared to its average volume of 51,248. The company has a fifty day moving average price of $83.66 and a two-hundred day moving average price of $71.15. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $98.44. The company has a market cap of $1.22 billion, a P/E ratio of 58.32 and a beta of 1.06.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Announces Dividend

The company also recently declared a special dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th will be given a $0.50 dividend. The ex-dividend date is Wednesday, December 17th. iRadimed’s payout ratio is 41.21%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Roth Capital set a $90.00 price objective on iRadimed in a research report on Friday, October 31st. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Lake Street Capital restated a “buy” rating and issued a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $87.33.

Institutional Investors Weigh In On iRadimed

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in iRadimed by 1.0% in the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after purchasing an additional 5,475 shares during the period. Geode Capital Management LLC raised its stake in iRadimed by 6.5% during the 2nd quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock worth $15,630,000 after buying an additional 15,996 shares during the period. Ranger Investment Management L.P. lifted its holdings in iRadimed by 7.4% during the second quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after acquiring an additional 14,730 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock valued at $8,889,000 after acquiring an additional 1,821 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of iRadimed by 10.9% in the first quarter. Acadian Asset Management LLC now owns 156,319 shares of the medical equipment provider’s stock worth $8,197,000 after acquiring an additional 15,329 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.